Moxifloxacin 0.5% + Dexamethasone 0.1% Eye DropsThird Party Manufacturing in India

Moxifloxacin 0.5% + Dexamethasone 0.1% Eye Drops combine an antibiotic and a corticosteroid in a single formulation for comprehensive management of ocular inflammation with bacterial infection or risk of infection.

Moxifloxacin is a fourth-generation fluoroquinolone that inhibits bacterial DNA replication by targeting DNA gyrase and topoisomerase IV. This provides broad-spectrum antibacterial coverage against common ocular pathogens including Staphylococcus species and Streptococcus pneumoniae.

Dexamethasone is a potent corticosteroid that acts by inhibiting phospholipase A2 and subsequently reducing the production of prostaglandins and leukotrienes. This suppresses the inflammatory response including edema erythema and cellular infiltration. The combination allows simultaneous anti-infective and anti-inflammatory treatment reducing the need for separate bottles and improving patient compliance.

The dual action makes this formulation particularly valuable for postoperative ophthalmic care and inflammatory eye conditions complicated by infection risk.

Therapeutic Uses

Moxifloxacin + Dexamethasone Eye Drops are prescribed for the treatment of:

• Post-Cataract Surgery Inflammation: Routine postoperative management of inflammation and antibiotic prophylaxis
• Post-Refractive Surgery: Post-LASIK PRK management to reduce inflammation and prevent secondary infection
• Blepharoconjunctivitis: Inflammatory blepharitis with associated bacterial infection
• Corneal Abrasion with Infection Risk: Corneal epithelial defects at risk of bacterial superinfection

Why Manufacturers Choose This Combination

Moxifloxacin + Dexamethasone is the standard of care in postoperative cataract management worldwide. Cataract surgeries account for millions of procedures annually in India alone driving consistent repeat demand for this combination. The fixed-dose combination offers convenience over separate bottles and is preferred by surgeons.

Indian manufacturers with sterile ophthalmic production lines and regulatory compliance for fixed-dose combinations can serve both domestic franchise markets and export territories. This is a high-volume product with strong brand loyalty once established in hospital formularies.